The prognosis of nonresectable @entity201 is dismal, and in Bismuth type III and IV @entity5 relief of @entity1087 is seldom achieved, despite successful endoprosthesis insertion. Therefore, we evaluated additional photodynamic therapy in @entity1 who failed to respond to endoprostheses insertion. All @entity1 showed good clinical results in regard to @entity1087 , quality of life; and survival time (median, 439 days). Before initiating a randomized multicenter trial we wanted to evaluate these preliminary results in a greater number of @entity1 . Twenty-one @entity1 underwent photodynamic therapy in addition to endoscopic drainage. The @entity3838 derivative @entity17654 was infused intravenously (2 mg/kg body weight), and intraluminal photoactivation was performed 2 days later. @entity648 decreased from a mean level of 201.26 +/- 189.25 micromol/l after stenting alone to 68.87 +/- 78.27 micromol/l (P = 0.0051), and the Karnofsky index improved from 49.04% +/- 28.79% to 72.85 +/- 19.01 (P = 0.003). Thirteen @entity1 have died and 8 @entity1 are still alive, with a follow-up period of 82-739 days. The 6-month survival time is 95%. Similar results were obtained by another group, with 75% overall (stage M1 and M0) survival after 6 months and beyond 80% for stage M0. Other authors treated 7 @entity1 and saw a remarkable reduction of @entity1157 and @entity648 decrease in all @entity1 .

Photodynamic therapy for XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity17654 :: ('MESH:D017323', 'Chemical') :: ['Photofrin'] @entity1087 :: ('MESH:D007565', 'Disease') :: ['jaundice'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumors'] @entity648 :: ('MESH:D001663', 'Chemical') :: ['Bilirubin', 'bilirubin'] @entity1157 :: ('MESH:D001649', 'Disease') :: ['bile duct stenosis'] @entity3838 :: ('MESH:D006415', 'Chemical') :: ['hematoporphyrin'] @entity201 :: ('MESH:D018281', 'Disease') :: ['cholangiocarcinoma']
@entity201 :: (MESH:D018281,Disease) :: ['cholangiocarcinoma']
